Trinity Biotech Announces Q2 2024 Financial Results
August 14, 2024 07:30 ET
|
Trinity Biotech plc
-Q2, 2024 total revenues of $15.8 million grew +14% Y/Y and +7.7% Q/Q based on strong demand and output in the TrinScreen HIV business- -Point-of-Care product revenue of $4.6 million grew 119% Y/Y...
Trinity Biotech to Announce Q2 2024 Financial Results
August 13, 2024 16:05 ET
|
Trinity Biotech plc
DUBLIN, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB) (the “Company”), a commercial stage biotechnology company focused on diabetes management solutions and human diagnostics,...
Trinity Biotech Obtains an Extension to Demonstrate Compliance With Nasdaq Listing Requirements
August 06, 2024 16:05 ET
|
Trinity Biotech plc
DUBLIN, Aug. 06, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial stage biotechnology company focused on human diagnostics and diabetes management solutions, including...
Trinity Biotech Provides Preliminary Second Quarter 2024 Update and Enters into UK Distribution Agreement with MedScience
August 02, 2024 09:24 ET
|
Trinity Biotech plc
-Second Quarter 2024 revenues are expected to fall between $15.5-$16.0 million, reflecting double digit percentage year over year growth- -Reiterating financial guidance of approximately $20 million...
Trinity Biotech Announces Appointment of A New CFO
July 09, 2024 16:05 ET
|
Trinity Biotech plc
DUBLIN, July 09, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB) a commercial stage biotechnology company focused on human diagnostics and diabetes management solutions, including...
Trinity Biotech to Begin European Pre-Pivotal Trial to Optimize its CGM Sensor
June 24, 2024 07:00 ET
|
Trinity Biotech plc
DUBLIN, June 24, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB) a commercial stage biotechnology company focused on human diagnostics and diabetes management solutions, including...
Trinity Biotech Attending 84th Scientific Sessions of the American Diabetes Association
June 10, 2024 09:10 ET
|
Trinity Biotech plc
DUBLIN, June 10, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB) (the “Company”), a commercial stage biotechnology company focused on diabetes management solutions and human diagnostics,...
Trinity Biotech Launches its Continuous Glucose Monitoring Microsite to Showcase its Innovative & Differentiated Technology
June 03, 2024 04:00 ET
|
Trinity Biotech plc
DUBLIN, June 03, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB) a commercial stage biotechnology company focused on human diagnostics and diabetes management solutions, including...
Trinity Biotech Announces Q1 2024 Financial Results and Reiterates Guidance
May 23, 2024 08:00 ET
|
Trinity Biotech plc
-Business performance on track to achieve approximately $20 million of annualized run-rate EBITDASO1 on annualized revenues of approximately $75 million by Q2 2025- -Strong sequential 39% Q/Q growth...
Trinity Biotech plc to Announce Q1 2024 Financial Results
May 21, 2024 16:05 ET
|
Trinity Biotech plc
DUBLIN, Ireland, May 21, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB) (the “Company”), a commercial stage biotechnology company focused on diabetes management solutions and human...